source
- Biohaven looks to take on Lilly in the muscle-sparing obesity spaceThey say that the way to make money in a gold rush is to open a shop selling picks and shovels. By the same token, perhaps companies can profit from the GLP-1 boom by developing ...Endpoints · 21d ago↗ source
- Prime wins gene editing dispute; Saol claims latest post-Makary FDA reversalAn arbitration panel ruled Prime didn’t breach a deal with Beam by developing a rare disease treatment. Elsewhere, European regulators are using a pancreatic cancer drug to test a new framework for…BioPharma Dive · 21d ago↗ source
- Sino Biopharm hooks AstraZeneca, GSK for separate respiratory partnershipsSino Biopharmaceutical announced drug development and sales pacts with two UK pharma companies on Wednesday. One will see the Hong Kong biotech license an investigational PDE3/4 inhibitor to AstraZ…